作者
Bhagyashri Navalkele, Jason M Pogue, Shigehiko Karino, Bakht Nishan, Madiha Salim, Shantanu Solanki, Amina Pervaiz, Nader Tashtoush, Hamadullah Shaikh, Sunitha Koppula, Jonathan Koons, Tanveer Hussain, William Perry, Richard Evans, Emily T Martin, Ryan P Mynatt, Kyle P Murray, Michael J Rybak, Keith S Kaye
发表日期
2017/1/15
期刊
Clinical Infectious Diseases
卷号
64
期号
2
页码范围
116-123
出版商
Oxford University Press
简介
Background
Recent evidence suggests that among patients receiving vancomycin, receipt of concomitant piperacillin–tazobactam increases the risk of nephrotoxicity. Well-controlled, adequately powered studies comparing rates of acute kidney injury (AKI) among patients receiving vancomycin + piperacillin–tazobactam (VPT) compared to similar patients receiving vancomycin + cefepime (VC) are lacking. In this study we compared the incidence of AKI among patients receiving combination therapy with VPT to a matched group receiving VC.
Methods
A retrospective, matched, cohort study was performed. Patients were eligible if they received combination therapy for ≥48 hours. Patients were excluded if their baseline serum creatinine was >1.2mg/dL or they were receiving renal replacement therapy. Patients receiving VC were matched to patients receiving VPT based on …
学术搜索中的文章
B Navalkele, JM Pogue, S Karino, B Nishan, M Salim… - Clinical Infectious Diseases, 2017